MedTrace Logo

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

NCT04179110 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-02-22

No results posted yet for this study

Summary

This study is designed to evaluate response and survival of treatment with the combination of pembrolizumab and ramucirumab in patients with progressive metastatic TCC after immune checkpoint inhibitor treatment.

Conditions

  • Transitional Cell Carcinoma

Interventions

DRUG

Pembrolizumab and Ramucirumab

Patients will receive Pembrolizumab 200 mg \& Ramucirumab 10 mg/kg every 3 weeks.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Michael Hurwitz, PhD, MD · Assistant Professor of Medicine (Medical Oncology) Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-18
Primary Completion
2022-12-15
Completion
2023-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04179110 on ClinicalTrials.gov